Geneva, April 20 -- International Clinical Trials Registry received information related to the study (NCT07521046) titled 'Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux in Myelofibrosis)' on April 2.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: University of Utah
Condition:
Myelofibrosis
Intervention:
Drug: ropeginterferon alfa- 2b
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: May 2026
Target Sample Size: 15
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/study/NCT075...